Search

Your search keyword '"A. RUSSELL JONES"' showing total 360 results

Search Constraints

Start Over You searched for: Author "A. RUSSELL JONES" Remove constraint Author: "A. RUSSELL JONES" Topic humans Remove constraint Topic: humans
360 results on '"A. RUSSELL JONES"'

Search Results

1. City-level vulnerability to temperature-related mortality in the USA and future projections: a geographically clustered meta-regression

2. Intrapulmonary shunting is a key contributor to hypoxia in COVID-19: An update on the pathophysiology

3. Characteristics and outcomes of patients with COVID-19 at a district general hospital in Surrey, UK

4. An Evaluation of the Safety of Pilots With Insulin-Treated Diabetes in Europe Flying Commercial and Noncommercial Aircraft

5. A potential diagnostic problem on the ICU: Euglycaemic diabetic Ketoacidosis associated with SGLT2 inhibition

6. The SGLT2 Inhibitor Dapagliflozin Increases the Oxidation of Ingested Fatty Acids to Ketones in Type 2 Diabetes

7. Safety attitudes in hospital emergency departments: a systematic review

8. Take Control: A randomized trial evaluating the efficacy and safety of self‐ versus physician‐managed titration of insulin glargine 300 U/mL in patients with uncontrolled type 2 diabetes

9. Efficacy of iGlarLixi in adults with type 2 diabetes inadequately controlled (glycated haemoglobin ≥8%, ≥64 mmol/mol) on two oral antidiabetes drugs: Post hoc analysis of the LixiLan-O randomized trial

11. Blood glucose monitoring by insulin-treated pilots of commercial and private aircraft: An analysis of out-of-range values

12. Pilots flying with insulin-treated diabetes

13. The use of routine blood tests to assist the diagnosis of COVID-19 in symptomatic hospitalized patients

14. Leveraging advances in diabetes technologies in primary care: a narrative review

15. Attitudes of doctors and nurses toward patient safety within emergency departments of two Saudi Arabian hospitals

16. Lessons for modern insulin development

17. Simultaneous Assessment of Clearance, Metabolism, Induction, and Drug-Drug Interaction Potential Using a Long-Term In Vitro Liver Model for a Novel Hepatitis B Virus Inhibitor

18. Efficacy and safety of fast‐acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52‐week, randomized, treat‐to‐target, phase III trial

19. Identification of barriers to insulin therapy and approaches to overcoming them

20. Effectiveness of a Decision Aid in Potentially Vulnerable Patients: A Secondary Analysis of the Chest Pain Choice Multicenter Randomized Trial

21. A review of the NG17 recommendations for the use of basal insulin in type 1 diabetes

22. Glycaemic benefit of iGlarLixi in insulin-naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan-O randomized trial

23. Non-invasive assessment of intrapulmonary shunt and ventilation to perfusion ratio in children with hepatopulmonary syndrome before and after liver transplantation

24. Basal insulin peglispro versus insulin glargine in insulin‐naïve type 2 diabetes: <scp>IMAGINE</scp> 2 randomized trial

25. Characterization of Pharmacokinetics in the Göttingen Minipig with Reference Human Drugs: An In Vitro and In Vivo Approach

26. A UK Civil Aviation Authority protocol to allow pilots with insulin-treated diabetes to fly commercial aircraft

27. USA joins Canada, UK, Ireland and Austria in allowing people with insulin‐treated diabetes to fly commercial aircraft

28. A single-center, open-label study investigating the excretion balance, pharmacokinetics, metabolism, and absolute bioavailability of a single oral dose of [

29. Patient power – Kidd Gloves

30. Lixisenatide reduces chylomicron triacylglycerol due to increased clearance

31. Shedding light on minipig drug metabolism – elevated amide hydrolysisin vitro

32. Liraglutide and Renal Outcomes in Type 2 Diabetes

33. Response to Comment on Russell-Jones et al. Diabetes Care 2017;40:943-950. Comment on Bowering et al. Diabetes Care 2017;40:951-957

34. Effect of subcutaneous insulin detemir on glucose flux and lipolysis during hyperglycaemia in people with type 1 diabetes

35. Impact of a Shared Decision Making Intervention on Health Care Utilization: A Secondary Analysis of the Chest Pain Choice Multicenter Randomized Trial

36. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes

37. Projected long-term outcomes in patients with type 1 diabetes treated with fast-acting insulin aspart vs conventional insulin aspart in the UK setting

38. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial

39. SGLT2 inhibitors in Type 1 diabetes: is this the future?

40. A brighter future for melanoma

41. Initial combination of linagliptin and metformin in patients with type 2 diabetes: efficacy and safety in a randomised, double-blind 1-year extension study

42. Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials

43. Gastric intrinsic factor: The gastric and small intestinal stages of cobalamin absorption. A personal journey

44. Aggressive epidermotropic cutaneous CD8+ lymphoma: A cutaneous lymphoma with distinct clinical and pathological features. Report of an EORTC Cutaneous Lymphoma Task Force Workshop

45. Can an interprofessional education tool improve healthcare professional confidence, knowledge and quality of inpatient diabetes care: a pilot study?

46. Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes (BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Trial With a 26-Week Extension

47. Shared decision making in patients with low risk chest pain: prospective randomized pragmatic trial

48. The Discovery of a Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor (PF-06273340) for the Treatment of Pain

49. Recent advances in incretin-based therapies

50. A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response

Catalog

Books, media, physical & digital resources